Type of Publication: | Journal article |
URI (citable link): | http://nbn-resolving.de/urn:nbn:de:bsz:352-280329 |
Author: | Heesen, Christoph; Kleiter, Ingo; Nguyen, Franziska; Schäffler, Nina; Kasper, Jürgen; Köpke, Sascha; Gaissmaier, Wolfgang |
Year of publication: | 2010 |
Published in: | Multiple Sclerosis ; 16 (2010), 12. - pp. 1507-1512. - ISSN 1352-4585. - eISSN 1477-0970 |
Pubmed ID: | 20826527 |
DOI (citable link): | https://dx.doi.org/10.1177/1352458510379819 |
Summary: |
Background:
Natalizumab is associated with the potentially life-threatening side-effect progressive multifocal leukoence- phalopathy (PML). Little is known about patients' and physicians' risk estimates and attitudes towards natalizumab treatment. Methods: Consecutive natalizumab-treated patients (n = 69) and neurologists (n = 66) in two centres and cooperating private practices received an evidence-based three-page information leaflet about natalizumab-associated PML and an evaluation sheet. Results: After reading the information, patients were significantly more likely than physicians to intend continuation of natalizumab treatment and willing to accept higher risks of PML: 49% of physicians would stop treatment at a PML risk of 2 : 10,000 or lower, while only 17% of patients would do so (p < 0.001). This difference could not be explained by risk calculation abilities or lack of understanding. Both groups overestimated natalizumab treatment effects. Conclusion: Patients had a significantly worse perception of multiple sclerosis as a malignant disease. We conclude that patients were willing to accept a higher risk of PML than neurologists. Coherent with their perception of risks and benefits, patients were also more willing to continue treatment. Open information about treatment-related risks is appreciated and might support shared decision making. |
Subject (DDC): | 150 Psychology |
Keywords: | multiple sclerosis, natalizumab, progressive multifocal leukoencephalopathy, risk perception, shared decision making |
Link to License: | In Copyright |
xmlui.ArtifactBrowser.ItemViewer.detail.textAllianzLicense | |
HEESEN, Christoph, Ingo KLEITER, Franziska NGUYEN, Nina SCHÄFFLER, Jürgen KASPER, Sascha KÖPKE, Wolfgang GAISSMAIER, 2010. Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists. In: Multiple Sclerosis. 16(12), pp. 1507-1512. ISSN 1352-4585. eISSN 1477-0970. Available under: doi: 10.1177/1352458510379819
@article{Heesen2010-12perce-28032, title={Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists}, year={2010}, doi={10.1177/1352458510379819}, number={12}, volume={16}, issn={1352-4585}, journal={Multiple Sclerosis}, pages={1507--1512}, author={Heesen, Christoph and Kleiter, Ingo and Nguyen, Franziska and Schäffler, Nina and Kasper, Jürgen and Köpke, Sascha and Gaissmaier, Wolfgang} }
Heesen_280329.pdf | 952 |